101 related articles for article (PubMed ID: 2128759)
21. Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors.
van Acker SA; Kramer K; Voest EE; Grimbergen JA; Zhang J; van der Vijgh WJ; Bast A
Cancer Chemother Pharmacol; 1996; 38(1):95-101. PubMed ID: 8603459
[TBL] [Abstract][Full Text] [Related]
22. Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia.
Baba H; Stephens LC; Strebel FR; Siddik ZH; Newman RA; Ohno S; Bull JM
Cancer Res; 1991 Jul; 51(13):3568-77. PubMed ID: 1905199
[TBL] [Abstract][Full Text] [Related]
23. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187.
Zhang J; Herman EH; Ferrans VJ
Am J Pathol; 1993 Jun; 142(6):1916-26. PubMed ID: 8506959
[TBL] [Abstract][Full Text] [Related]
25. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Herman EH; Zhang J; Hasinoff BB; Chadwick DP; Clark JR; Ferrans VJ
Cancer Chemother Pharmacol; 1997; 40(5):400-8. PubMed ID: 9272116
[TBL] [Abstract][Full Text] [Related]
27. Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits.
Herman EH; Ferrans VJ; Jordan W; Ardalan B
Res Commun Chem Pathol Pharmacol; 1981 Jan; 31(1):85-97. PubMed ID: 6789416
[TBL] [Abstract][Full Text] [Related]
28. Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids.
Hüsken BC; de Jong J; Beekman B; Onderwater RC; van der Vijgh WJ; Bast A
Cancer Chemother Pharmacol; 1995; 37(1-2):55-62. PubMed ID: 7497597
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of the protective activity of ICRF-187 against alloxan-induced diabetes in mice.
el-Hage A; Herman EH; Yang GC; Crouch RK; Ferrans VJ
Res Commun Chem Pathol Pharmacol; 1986 Jun; 52(3):341-60. PubMed ID: 3090662
[TBL] [Abstract][Full Text] [Related]
30. Effects of Doxorubicin (Adriamycin) and [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)]propane (ICRF-187) on skeletal muscle protease activities.
Zima T; Tesar V; Richardson PJ; Mantle D; Preedy VR
Toxicol Appl Pharmacol; 2001 Mar; 171(3):135-40. PubMed ID: 11243912
[TBL] [Abstract][Full Text] [Related]
31. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat.
Yeung TK; Jaenke RS; Wilding D; Creighton AM; Hopewell JW
Cancer Chemother Pharmacol; 1992; 30(1):58-64. PubMed ID: 1586981
[TBL] [Abstract][Full Text] [Related]
32. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane).
Gorbsky GJ
Cancer Res; 1994 Feb; 54(4):1042-8. PubMed ID: 8313360
[TBL] [Abstract][Full Text] [Related]
33. Isolated mouse atrium as a model to study anthracycline cardiotoxicity: the role of the beta-adrenoceptor system and reactive oxygen species.
de Jong J; Schoofs PR; Onderwater RC; van der Vijgh WJ; Pinedo HM; Bast A
Res Commun Chem Pathol Pharmacol; 1990 Jun; 68(3):275-89. PubMed ID: 2166963
[TBL] [Abstract][Full Text] [Related]
34. The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin.
Hasinoff BB
Agents Actions; 1989 Mar; 26(3-4):378-85. PubMed ID: 2544086
[TBL] [Abstract][Full Text] [Related]
35. Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells.
Shipp NG; Dorr RT; Alberts DS; Dawson BV; Hendrix M
Cancer Res; 1993 Feb; 53(3):550-6. PubMed ID: 8425187
[TBL] [Abstract][Full Text] [Related]
36. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
Saad SY; Najjar TA; Alashari M
J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
[TBL] [Abstract][Full Text] [Related]
37. Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.
de Beer EL; Bottone AE; van Rijk MC; van der Velden J; Voest EE
Br J Pharmacol; 2002 Apr; 135(7):1707-14. PubMed ID: 11934811
[TBL] [Abstract][Full Text] [Related]
38. In vivo effects of doxorubicin and isoproterenol on reduced glutathione and H2O2 production in mouse heart.
D'Alessandro N; Rausa L; Crescimanno M
Res Commun Chem Pathol Pharmacol; 1988 Oct; 62(1):19-30. PubMed ID: 3205977
[TBL] [Abstract][Full Text] [Related]
39. Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159).
Herman EH; Ferrans VJ; Bhat HB; Witiak DT
Cancer Chemother Pharmacol; 1987; 19(4):277-81. PubMed ID: 3594714
[TBL] [Abstract][Full Text] [Related]
40. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
Wexler LH; Andrich MP; Venzon D; Berg SL; Weaver-McClure L; Chen CC; Dilsizian V; Avila N; Jarosinski P; Balis FM; Poplack DG; Horowitz ME
J Clin Oncol; 1996 Feb; 14(2):362-72. PubMed ID: 8636745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
